Steven Mnuchin waded into an unexpectedly murky swamp on Thursday: answering for undisclosed interests and millions of dollars in assets.
The executive/activist team that generated impressive results north of the border are preparing to target CSX. Their resumes are exciting, but investors should be cautious.
The South Korean tech giant has struggled in recent months with malfunctioning products and a political scandal involving the company's vice chairman.
Analysts really liked the streaming giant's stellar fourth quarter results, with many increasing their price targets.
Sorry investors, your post-election honeymoon is about to be over: at noon tomorrow, the Trump rally will get real.
What you need to know.
Insiders at these companies -- including Kindred Biosciences and Regeneron Pharmaceuticals -- have been scooping up shares of their own stock lately.
The former governor of Texas begins his confirmation hearing for the job he once said he would abolish.
These charts explain it all.
There could be a major windfall for Fortune 500 companies.
A Trump administration could make precious metals an investor's best friend.
Mnuchin said he wants a simpler tax code but gave few specifics. He also dodged questions about his own taxes.
The autoinjector will be free for insured patients and those whose annual income is less than $100,000 yearly.
U.S. stocks hold lower one day before the inauguration of President-elect Trump.
Former Goldman Sachs executive Steve Mnuchin was questioned about his offshore entities by Sen. Ron Wyden (D-OR) Thursday morning.
The Dow Jones Industrial Average falls for its fifth straight session on Thursday, further distancing itself from recent records, in the countdown to the inauguration of President-elect Donald Trump.
TheStreet's Jim Cramer says the department stores have been 'disappointing' but did point out a couple which could carry momentum to the upside.
The rewards of this strategy more than justify the risks.
Fed speakers are sounding to hawkish and need to tone it down, according to Real Money contributor Stephen Guilfoyle.
Pfizer is working on its eighth straight loss after failing near heavy resistance.
The retailer has lowered its guidance for fiscal fourth-quarter profit and revenue following a weak November and December.
Should you get on board with railroad stocks? Here's what Jim Cramer thinks.
Check out Jim and TheStreet editorial team’s latest analysis and commentary on what’s moving markets now.